NYSE: CRLCharles River Laboratories

    Charles River Laboratories: results and news

    Every Charles River Laboratories filing with the US SEC that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings, mergers & acquisitions.

    2 articles · Health Care · Latest 10 Nov 2026

    Lab technicians in blue scrubs working with automated analysis machines in a bright clinical laboratory

    NYSE: CRLCharles River Laboratories

    Charles River Laboratories Q3 2026 Results: Net Income $333 Million on Revenue of $983 Million

    Charles River Laboratories (NYSE: CRL) reported third-quarter 2026 results for the quarter ended 26 Sep 2026. GAAP revenue was $982.7 million and GAAP net income attributable to common shareholders was $333.1 million, it said on 4 Nov 2026. GAAP diluted EPS was $6.86, and adjusted EPS, a company-defined non-GAAP measure, was $3.09.

    • US stocks
    • Earnings

    Blacklitt Research3 min read